Lopez-Vicario et al. further corroborated the ability of sEH inhibition to attenuate hepatic steatosis and inflammation (e.g., decreased macrophage infiltration, chemokine and pro-inflammatory cytokine production, and increased expression of the pro-resolution cytokine IL10) [42]. Here, EPHX2 is linked to fatty liver disease.